Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2

The activated JAK2-V617F mutant is very frequently found in myeloproliferative neoplasms (MPNs), and its inhibitor ruxolitinib has been in clinical use, albeit with limited efficacies. Here, we examine the signaling mechanisms from JAK2-V617F and responses to ruxolitinib in JAK2-V617F-positive leuke...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishida, Shinya, Akiyama, Hiroki, Umezawa, Yoshihiro, Okada, Keigo, Nogami, Ayako, Oshikawa, Gaku, Nagao, Toshikage, Miura, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003557/
https://www.ncbi.nlm.nih.gov/pubmed/29928488
http://dx.doi.org/10.18632/oncotarget.25515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003557/
https://www.ncbi.nlm.nih.gov/pubmed/29928488
http://dx.doi.org/10.18632/oncotarget.25515

Ejemplares similares